Engagement of the Pd-1 Immunoinhibitory Receptor by a Novel B7 Family Member Leads to Negative Regulation of Lymphocyte Activation

Gordon J. Freeman, Andrew J. Long, Yoshiko Iwai, +16

The Journal of Experimental Medicine

PD-L2 is a second ligand for PD-1 and inhibits T cell activation

Yvette Latchman, Clive R. Wood, Tatyana Chernova, +18

Nature Immunology

Cancer ImmunosurveillanceSignal TransductionImmunologySecond LigandImmunologic Mechanism +6

In vitro and in vivo characterization of the JAK1 selectivity of upadacitinib (ABT-494)

Julie Parmentier, J W Voss, Candace Graff, +11

BMC Rheumatology

Characterization of murine Flt4 ligand/VEGF-C

Lori Fitz, John C. Morris, Paul Towler, +15

Oncogene

Growth HormoneImmunologyMurine Flt4 Ligand/vegf-cMedicineCell Biology +1

The JAK1 Selective Inhibitor ABT 317 Blocks Signaling Through Interferon-γ and Common γ Chain Cytokine Receptors to Reverse Autoimmune Diabetes in NOD Mice

Tingting Ge, Gaurang Jhala, Stacey Fynch, +10

Frontiers in Immunology

ABBV-105, a selective and irreversible inhibitor of Bruton’s tyrosine kinase, is efficacious in multiple preclinical models of inflammation

Christian Goess, Christopher M. Harris, Sara Murdock, +8

Modern Rheumatology

Synovial Inflammatory Pathways Characterize <scp>Anti‐TNF</scp>–Responsive Rheumatoid Arthritis Patients

Jing Wang, Donna Conlon, Felice Rivellese, +9

Arthritis & Rheumatology

RA-MAP, molecular immunological landscapes in early rheumatoid arthritis and healthy vaccine recipients

John D. Isaacs, Sarah Brockbank, Ayako Wakatsuki Pedersen, +147

Scientific Data

STAT3 phosphorylation mediates the stimulatory effects of interferon alpha on B cell differentiation and activation in SLE

Aurélie De Groof, Julie Ducreux, Floor Aleva, +6

Lara D. Veeken

FRI0131 ELUCIDATING THE MECHANISM UNDERLYING CREATINE PHOSPHOKINASE UPREGULATION WITH UPADACITINIB

Kara L. Queeney, William Housley, Jeremy Sokolov, +1

Annals of the Rheumatic Diseases